Yervoy Fails to Shut Down Prostate Cancer but Could Be Effective in a Combo Therapy

Yervoy Fails to Shut Down Prostate Cancer but Could Be Effective in a Combo Therapy
Although the anti-CTLA-4 agent Yervoy (ipilimumab) opens the door to more anti-tumor T-cells entering a prostate-cancer tumor, the treatment produces little patient benefit, a clinical trial indicates. Yerboy activates the immune system by going after the CTLA-4 protein receptor that slows immune-system activity. But prostate cancer responds to Yerboy by increasing the expression of two other immune checkpoint molecules, PD-L1 and VISTA. And both send a don't-eat-me signal to immune cells. That reaction is why Yerboy, by itself, offers little patient benefit. The study suggests that combining Yervoy with PD-1 and VISTA inhibitors could be a way to treat prostate cancer patients, however. The research, “VI
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *